Pharmaceuticals, Biotechnology and Life Sciences
Latest findings from multicenter trial demonstrate Signatera’s ability to improve risk stratification for patients with therapy-resistant disease AUSTIN, Texas–(BUSINESS WIRE)–Natera,…
Combination achieved an additional 4.5% mean weight loss vs. tirzepatide alone with no plateau at 24 weeks Improvements observed in…
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in…
New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation…
– Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase…
First CTA authorization marks nChroma’s transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early…
BOSTON & SHANGHAI–(BUSINESS WIRE)–Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions,…
Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term Growth Reaffirms Full-Year 2025 Adjusted(1) Diluted EPS Guidance(2)…
HANGZHOU, China–(BUSINESS WIRE)–Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA…
LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration.…